FLT3 and acute myeloid leukemia: For newly diagnosed, fit patients with FLT3-mutated AML, the standard of care is defined by the phase III RATIFY trial, in which patients with FLT3-ITD or -TKD mutated AML were randomized to standard induction and consolidation chemotherapy ± midostaurin [25].